Are you a Knight ADRC affiliated researcher with a news article you would like us to post?
Contact Us
Patient defies genetic fate to avoid Alzheimer’s (Links to an external site)
Doug Whitney, who lives near Seattle, Wash., inherited a mutation that has caused many family members to develop Alzheimer’s disease at about age 50, yet he shows no sign of the illness at age 75. His case is the subject of a new study by WashU Medicine researchers that aims to identify potential routes to preventing or treating Alzheimer’s based on Whitney’s exceptional resilience to the disease.
Two Alzheimer’s drugs help patients live independently at home for longer periods (Links to an external site)
Lecanemab (Leqembi) and donanemab (Kisunla) could slow cognitive decline, but side effects exist.
Anti-amyloid treatments: Why we think they are worth it (Links to an external site)
Years of experience watching our patients progressively decline and die from complications of Alzheimer’s disease (AD) has strongly motivated us to provide newly approved anti-amyloid treatments to appropriate patients. Following detailed and personalized discussions of the potential risks and benefits of these treatments with patients and their families, almost 300 patients at our clinic have chosen to receive lecanemab infusions
Next-gen Alzheimer’s drugs extend independent living by month (Links to an external site)
New analysis recasts benefits of treatment in relation to day-to-day impacts on patients’ lives
International Alzheimer’s prevention trial in young adults begins (Links to an external site)
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise